Company Overview
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Why Investors Should Care
Revenue has grown at a 724.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $100.25M (+53.9% YoY); net profit $-73.20M.
- Trailing 12 Months Year-on-year growth — revenue +56.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 724.3%, profit CAGR -4.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 724.29% |
| 1 Year: | 56.60% |
Compounded Profit Growth
| 5 Years: | -4.35% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +31.41% |
| 6 Months: | -16.29% |
| 3 Months: | +58.61% |
| 1 Month: | +14.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)63.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 724.3% over 5 years.
CONS
- Earnings shrank at -4.3% CAGR over 5 years.
- Trading 47.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BBNX Beta Bionics, Inc. R2K | 16.86 | -12.31 | $751.31M | 0.00% | -24.07% | -22.71% | 724.29% | -4.35% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.93M | 15.05M | - | - | 17.64M | 23.24M | 27.25M | 32.12M | 27.63M |
| Cost of Revenue | - | - | - | - | 8.67M | 10.73M | 12.13M | 13.18M | 11.19M |
| Gross Profit | 7.20M | 8.08M | - | - | 8.97M | 12.50M | 15.12M | 18.94M | 16.44M |
| Operating Expenses | - | - | - | - | 27.61M | 32.38M | 32.16M | 35.07M | 40.71M |
| Operating Income | -9.45M | -11.78M | - | - | -18.64M | -19.87M | -17.04M | -16.12M | -24.27M |
| EBITDA | - | - | - | - | -18.04M | -19.22M | -16.36M | -11.01M | -23.28M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -28.66M | -16.87M | -14.21M | -13.47M | -21.89M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -12.45M | -14.46M | - | - | -28.66M | -16.87M | -14.21M | -13.47M | -21.89M |
| Diluted EPS | -2.07 | -2.37 | - | - | -0.93 | -0.39 | -0.33 | -0.30 | -0.49 |
| R&D Expense | 5.48M | 6.35M | 5.14M | - | 7.59M | 8.87M | 8.20M | - | 10.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 179.00K | 11.99M | 65.12M | 100.25M |
| Cost of Revenue | - | 5.69M | 29.24M | 44.71M |
| Gross Profit | 179.00K | 6.31M | 35.89M | 55.54M |
| Operating Expenses | 66.02M | 42.16M | 81.14M | 127.22M |
| Operating Income | -65.84M | -35.85M | -45.25M | -71.68M |
| EBITDA | -62.65M | -33.76M | -42.97M | -68.81M |
| Interest Expense | 14.00K | 68.00K | - | - |
| Pretax Income | -64.75M | -44.10M | -54.76M | -73.20M |
| Tax Provision | - | - | - | - |
| Net Income | -64.75M | -44.10M | -54.76M | -73.20M |
| Diluted EPS | -2.12 | -1.45 | -1.28 | -1.81 |
| R&D Expense | - | 17.94M | 26.18M | 34.79M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 35.53M | 110.04M | 149.65M | 328.74M |
| Current Assets | 28.47M | 103.62M | 132.92M | 267.90M |
| Cash & Equivalents | 27.68M | 26.57M | 30.43M | 31.58M |
| Inventory | 0 | 1.25M | 13.32M | 21.72M |
| Receivables | 0 | 4.45M | 12.00M | 17.12M |
| Total Liabilities | 205.56M | 313.14M | 395.00M | 41.13M |
| Current Liabilities | 8.87M | 10.61M | 21.15M | 30.92M |
| Long Term Debt | - | - | - | - |
| Total Debt | 4.13M | 4.22M | 7.25M | 7.30M |
| Total Equity | -170.03M | -203.10M | -245.36M | 287.61M |
| Shares Outstanding | 42.86M | 42.86M | 42.86M | 44.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -60.21M | -32.45M | -48.27M | -50.92M |
| Investing Cash Flow | -769.00K | -69.69M | -3.48M | -162.81M |
| Financing Cash Flow | 56.78M | 101.03M | 55.62M | 214.87M |
| Capital Expenditure | -772.00K | -402.00K | -3.40M | -5.30M |
| Free Cash Flow | -60.98M | -32.85M | -51.67M | -56.22M |
| Net Change in Cash | -4.20M | -1.11M | 3.87M | 1.14M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 100.0% | 52.6% | 55.1% | 55.4% |
| Operating Margin % | -36,784.4% | -298.9% | -69.5% | -71.5% |
| Net Margin % | -36,173.7% | -367.6% | -84.1% | -73.0% |
| ROE % | 38.1% | 21.7% | 22.3% | -25.5% |
| ROCE % | -247.0% | -36.1% | -35.2% | -24.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Eventide Asset Management LLC | 13.34% | 5.95M | $99.99M |
| 2 | Soleus Capital Management, L.P. | 9.77% | 4.35M | $73.24M |
| 3 | Morgan Stanley | 9.49% | 4.23M | $71.10M |
| 4 | Sands Capital Alternatives, LLC | 8.32% | 3.71M | $62.36M |
| 5 | Farallon Capital Management LLC | 8.10% | 3.61M | $60.68M |
| 6 | Blackrock Inc. | 6.82% | 3.04M | $51.10M |
| 7 | Point72 Asset Management, L.P. | 5.67% | 2.53M | $42.47M |
| 8 | Vestal Point Capital, LP | 4.96% | 2.21M | $37.19M |
| 9 | RTW Investments LP | 4.49% | 2.00M | $33.64M |
| 10 | Vanguard Capital Management LLC | 3.88% | 1.73M | $29.06M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BBNX
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financia…
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
New dashboard at betabionics.com shows every patient, every baseline, every outcome, with no filters and no fine printIRVINE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the developmen…
Beta Bionics to launch its first insulin patch pump to compete with Insulet
The device called Mint, which would work with the company’s adaptive insulin dosing algorithm, is expected to debut in the first half of 2027.
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end of …
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.
Robert Bruce's Strategic Moves: A Closer Look at Beta Bionics Inc's Impactful Addition
Exploring the Latest 13F Filing and Investment Strategies
BBNX — Frequently Asked Questions
What is the current share price of Beta Bionics, Inc. (BBNX)?
As of 2026-07-14 21:23 PDT, Beta Bionics, Inc. (BBNX) trades at $16.86 on NasdaqGM. Its 52-week range is $8.86 to $31.99.
What is the market capitalisation of BBNX?
Beta Bionics, Inc. (BBNX) has a market capitalisation of $751.31M on NasdaqGM.
What is the P/E ratio of BBNX?
BBNX trades at a trailing price-to-earnings (P/E) ratio of -12.31. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.39.
What is the return on equity (ROE) of BBNX?
BBNX has a return on equity (ROE) of -22.71%. Its return on capital employed (ROCE) is -24.07%.
Is BBNX a good stock to buy?
This page provides a data-driven analysis of Beta Bionics, Inc. (BBNX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.